Therapeutic Efficacy of Spironolactone for Central Serous Chorioretinopathy
January 2022
in “Yonsei Medical Journal”
TLDR Spironolactone helps reduce fluid in the eye in Central Serous Chorioretinopathy, but doesn't improve vision and recurrence is common.
The research evaluated the effects of oral Spironolactone (SPRL) on 103 patients with Central Serous Chorioretinopathy (CSC). It found that SPRL significantly improved central macular thickness, subretinal fluid (SRF) height, and subfoveal choroidal thickness at 1, 3, and 6 months after therapy. However, best-corrected visual acuity didn't significantly change. Complete resolution of SRF was higher in chronic CSC patients than in acute CSC patients at 1 month (21.1% vs. 6.0%). Recurrence occurred in 14 (13.1%) eyes after complete SRF resolution, with older age, more previous intravitreal bevacizumab injections, and poor initial visual acuity associated with recurrence. No permanent adverse effects were observed, but one patient experienced increased hair loss after 1 month of SPRL use. The study concluded that SPRL showed therapeutic benefits in CSC patients in terms of SRF resolution, but recurrence was relatively frequent, especially in older patients.
View this study on eymj.org →
Cited in this study
research Oral medications for central serous chorioretinopathy: a literature review
Some oral medications may help treat central serous chorioretinopathy, especially eplerenone, but more research is needed.
research Female pattern alopecia: current perspectives
Female pattern hair loss is caused by multiple factors and while treatments like topical minoxidil, hormone therapy, and low-level light therapy can help, none can fully cure it.